Hologic (NSDQ:HOLX) said today it is launching the MyoSure Reach device, designed to manage hard-to-Reach uterine pathology to access the upper third of the uterine cavity.
The addition is an expansion of its already released MyoSure gynecological surgical products, the Marlborough, Mass.-based company said. The MyoSure tissue removal system is designed for the removal of polyps and fibroids which can cause abnormal uterine bleeding.
“The ability to remove hard-to-reach intrauterine pathology is an important enhancement for the MyoSure system, and it demonstrates Hologic’s dedication to women’s health. The MyoSure Reach device offers the benefits of the current device, plus expanded capabilities to remove pathology in the upper third of the uterine cavity,” medical affairs veep Dr. Edward Evantash said in a press release.
The newly launched product allows the operating physician to remove tissue 3 times closer to the uterine wall and remove 25% more tissue, the Marlborough, Mass.-based company said.
“The MyoSure Reach device helps physicians better meet the needs of their patients by providing them an efficient and effective solution for pathology removal. The MyoSure Reach device is an exciting addition to Hologic’s suite of gynecologic solutions, which are quick and effective for physicians and patients,” Hologic GYN surgical solutions division prez Tom O’Neill said in prepared remarks.
Last month, Hologic released 2nd quarter 2016 earnings that beat the street and provided new guidance for the 2nd half of the year.
The company reported profits of $68.9 million, or 24¢ per share, on sales of $693.3 million for the 3 months ended March 26, 2016. That amounts to a 44.1% bottom-line gain as sales grew 5.8% compared with the same period in 2015.
Adjusted to exclude 1-time items, earnings per share were 47¢, squeaking by Wall Street analysts estimates of 46¢. The company topped the Street’s rev estimates by just under $6 million.
The post Hologic launches new MyoSure Reach device appeared first on MassDevice.
from MassDevice http://ift.tt/1OicLCj
Cap comentari:
Publica un comentari a l'entrada